TickerFacts.

Autolus Therapeutics plc (AUTL): Cost of Revenue

Annual figures by period end, from SEC filings.

$96.37M
Year ended 2025-12-31
$99.01M
Trailing 12 months to 2026-06-30
2023-12-31: $02024-12-31: $11.39M2025-12-31: $96.37M$96.37M
2023-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$96.37M+746.3%2026-03-27, From 2025-01-01
2024-12-31$11.39Mn/a2026-03-27, From 2024-01-01
2023-12-31$0n/a2025-03-20, From 2023-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Autolus Therapeutics plc (AUTL)2025-12-31$96.37M+746.3%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$70.95M+56.8%
Compugen Ltd (CGEN)2025-12-31$9.25M+16.7%
Vir Biotechnology, Inc. (VIR)2025-12-31$26.0K-96.9%
Champions Oncology, Inc. (CSBR)2026-04-30$30.90M+8.8%
Protalix BioTherapeutics, Inc. (PLX)2025-12-31$26.99M+11.0%
ImmunityBio, Inc. (IBRX)2025-12-31$753.0Kn/a
Agenus Inc (AGEN)2025-12-31$1.02M+110.3%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$39.21M-16.7%

Compare AUTL, RXRX, CGEN, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗